ConvaTec Group H1 Earnings Call Highlights

3 weeks ago 13

MarketBeat

Tue, August 4, 2026 astatine 5:03 AM CDT 6 min read

Key Points

ConvaTec Group (LON:CTEC) said it remained connected way to conscionable its 2026 fiscal targets aft reporting 5% integrated gross maturation successful the archetypal half, excluding the interaction of its InnovaMatrix skin-substitute product.

The institution said gross maturation was broad-based crossed its 4 chronic-care categories, portion it continued to put successful manufacturing capacity, new-product launches, simplification programs and technology. Management reiterated its anticipation that maturation volition accelerate successful the 2nd half, led principally by Infusion Care.

→ Lost successful Space: Why Aerospace Valuations Are Plummeting Right Now

First-half operating borderline was 21.2%, down 10 ground points from a twelvemonth earlier but up 50 ground points astatine changeless currency. Adjusted net per stock roseate 6%, with the institution maintaining its anticipation for double-digit EPS maturation for the afloat year.

Chief Financial Officer Fiona Ryder said ConvaTec expects astir 100% free-cash-flow-to-equity conversion for 2026 contempt little first-half currency flow, which reflected working-capital timing and maturation superior expenditures. The institution accrued its interim dividend by 15% and announced a £200 cardinal stock buyback programme to beryllium completed by year-end.

InnovaMatrix Creates Revenue and Margin Headwind

→ MarketBeat Week successful Review – 07/27- 07/31

InnovaMatrix income fell £37 cardinal twelvemonth implicit twelvemonth to £2.5 cardinal successful the archetypal half, creating a small much than a 3% headwind to radical gross growth. ConvaTec present expects InnovaMatrix gross of £5 cardinal to £10 cardinal for the afloat year, compared with erstwhile expectations, representing an estimated 2.5% headwind to yearly radical gross growth.

Read Entire Article